Back to results
US 11,083,786 B2Granted
Induce and enhance immune responses using recombinant replicon systems
AssigneeJanssen Pharmaceuticals, Inc.
InventorsKurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.
Claims24
A method for inducing an immune response in a subject, comprising:
- administering to the subject at least one dose of a priming composition comprising a first RNA replicon which encodes a first antigen;
- and
- subsequently administering to the subject at least one dose of a boosting composition comprising a second heterologous RNA replicon which encodes a second antigen,
- wherein the first and second RNA replicons are different from each other, and
- the first RNA replicon is derived from equine arteritis virus (EAV) and the second RNA replicon is derived from an alphavirus species.
2 more elements
A method for delivering two RNA replicons into a subject, comprising
- administering to the subject a first nucleic acid sequence encoding a first RNA replicon which encodes a first antigen;
- and
- subsequently administering to the subject, a second nucleic acid sequence encoding a second heterologous RNA replicon which encodes a second antigen,
- wherein the first and second RNA replicons are different from each other, and
- the first RNA replicon is derived from equine arteritis virus (EAV) and the second RNA replicon is derived from an alphavirus species.
2 more elements
Dependencies are inferred from the claim text.